Top

mobilizing

the wisdom to heal

The expertise to transform the way challenging diseases and conditions are treated

Noveome is a clinical-stage biopharmaceutical company advancing ST266— a first-of-its-kind, multi-targeted secretome containing hundreds of biologically active proteins and other factors crucial to neuroprotection, the modulation of inflammation, cell recovery and healing.

ST266 contains physiologic levels of hundreds of active biomolecules, including growth factors and cytokines. These molecules modulate a host of biological pathways, including anti-inflammatory and neuroprotective mechanisms, critical to healing. Learn more about the science behind ST266 >

In both preclinical and clinical studies, ST266 has been shown to be well-tolerated with demonstrated biologic activity. We believe it holds significant promise to improve clinical outcomes in a range of complex diseases and conditions in categories as diverse as ophthalmology, neurology, dermatology and more. Explore our advancing pipeline >

leadership

Our experienced management team has an established track record of advancing promising drug candidates from discovery through development and commercialization.

Christopher J. P. Velis

CEO

BIO

Kevin E. McCracken

Chief Operating Officer

BIO

Nisha Varma

Vice President and Assistant to the CEO

BIO

Larry R. Brown, Sc.D.

Research & Development Executive Vice President/Chief Scientific Officer

BIO

Randall R. Rupp, Ph.D.

Executive Vice President of Manufacturing and Development

BIO

David L. Steed, M.D.

Executive VP of Medical Affairs, Chief Medical Officer

BIO

Anne Urling

Vice President of Clinical Operations

BIO

Maria Weber, CPA

Vice President of Administration & Controller

BIO

board of directors

We are advised by an independent Board of Directors that includes experts in healthcare technology, intellectual property, investment and management.

William J. Golden, CFA

Founder and Chairman

BIO

Ronald K. Poropatich M.D., M.S.

Board Member

BIO

Christopher J. P. Velis

Board Member

BIO

Annamaria T. Kausz, M.D., M.S.

Board Member

BIO

Robert S. Langer, Sc.D.

Board Member

BIO

Patrick T. Welch

Board Member

BIO

John H. McArthur – In Memoriam

Board Member

BIO

scientific
advisory board

Noveome’s Scientific Advisory Board provides external review and scientific judgment to assist in Noveome’s development of its platform biologic ST266.

Chairman, Robert S. Langer, Sc.D.

Massachusetts Institute of Technology

BIO

Matthew Spite, Ph.D.

Harvard University

BIO

Si M. Pham, M.D.

Mayo Clinic

BIO

Elof Eriksson, M.D., Ph.D.

Harvard Medical School

BIO

Ronald K. Poropatich M.D., M.S.

University of Pittsburgh

BIO

Mathew D. Neal, M.D.

University of Pittsburgh

BIO

David J. Hackam, M.D., Ph.D.

Johns Hopkins University

BIO

Lee E. Goldstein, M.D., Ph.D.

Boston University

BIO

Pedram Hamrah, M.D.

Tufts University School of Medicine

BIO

Leah R. Hanson, Ph.D.

Health Partners Institute

BIO

José-Alain Sahel, M.D.

University of Pittsburgh, UPMC Eye Center, Eye and Ear Foundation

BIO

Kenneth S. Shindler, M.D., Ph.D.

University of Pennsylvania

BIO

Thomas Van Dyke, D.M.D., Ph.D.

Forsyth Institute

BIO

contact us

Noveome received seed funding and access to world-class researchers, physicians and experts in private and public reimbursement at Pittsburgh ‘s leading healthcare institutions, including UPMC Health System, Highmark Blue Cross/Blue Shield, the University of Pittsburgh and Carnegie Mellon University. We are passionate about helping the Pittsburgh region grow into the world’s next great nexus for biotechnology.

Corporate Headquarters
100 Technology Drive, Suite 200
Pittsburgh, PA 15219

Telephone
Call us at: +1.412.402.9914

General inquiries
Please contact us at:
info@noveome.com

Clinical inquiries
Please contact us at:
clinical@noveome.com

Patients
For urgent clinical inquiries,
please contact your treating physician
or clinical study investigator.

Healthcare Professionals
Please contact us at:
clinical@noveome.com

Investor Inquiries
Please contact:

Current Investors:
Investor@noveome.com

For Investment Opportunities:
Invest@noveome.com